Helen Shaw is a qualified doctor with over 20 years' experience as a medical professional in the pharmaceutical industry. She has a proven track record in providing strategic direction and focus in product development and innovation and her experience covers all drug and device classifications, and all stages of development and marketing, in a global arena. Helen’s expertise is in providing leadership and strategic direction at Board level, fostering excellent relationships with key stakeholders and regulatory authorities and translating technical and regulatory needs into clear development programmes to maximise shareholder value.
Helen is a non-executive board member of Mode Health and has been a non-executive board member with Zilico Ltd, Syntopix Group plc. and Auralis Ltd. She is Chairman of Four Shaw Consulting Ltd and co-managing director of Proveca. As Medical Director of Boots Healthcare International Helen had a strong track record in international product development, prescription to over-the-counter switching, in-licensing and joint ventures for brands such as Clearasil, Nurofen, Strepsils and Optrex. As non-executive Medical Director to Auralis Ltd, Helen provided key strategic and hands-on input to the development portfolio and product licensing, including gaining the PUMA for Buccolam.